Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003789 · ClinicalTrials.gov registry record · Phase 3
Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 216
- Enrollment target
NCT00003789: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00003789 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 216 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003789, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 216 participants
- Enrollment target
Study Summary
Randomized phase III trial to compare the effectiveness of hyperthermic isolated limb perfusion of melphalan with or without tumor necrosis factor in treating patients who have locally advanced melanoma of the arm or leg. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Heating melphalan to several degrees above body temperature and infusing it only to the area around the tumor may kill more tumor cells. It is not yet known whether combining melphalan with tumor necrosis factor is more effective than melphalan alone in treating melanoma.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG melphalan
- DRUG isolated limb perfusion
- BIOLOGICAL recombinant tumor necrosis factor family protein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 1999-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003789
The ClinicalTrials.gov registry entry for NCT00003789 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00003789 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003789 about?
NCT00003789 is a clinical study titled "Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg". Randomized phase III trial to compare the effectiveness of hyperthermic isolated limb perfusion of melphalan with or without tumor necrosis factor in treating patients who have locally advanced melanoma of the arm or leg. Drugs used in chemotherapy use different ways to stop tumor cells from dividin...
What is the current status of trial NCT00003789?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 216 participants. The study started on 1999-03.
What interventions are being tested in trial NCT00003789?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), melphalan (DRUG), isolated limb perfusion (DRUG), recombinant tumor necrosis factor family protein (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003789?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.